HomeCompareCWCO vs BDX

CWCO vs BDX: Dividend Comparison 2026

CWCO yields 1.61% · BDX yields 2.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CWCO wins by $39.5K in total portfolio value· pulled ahead in Year 2
10 years
CWCO
CWCO
● Live price
1.61%
Share price
$33.01
Annual div
$0.53
5Y div CAGR
46.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.4K
Annual income
$18,351.00
Full CWCO calculator →
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →

Portfolio growth — CWCO vs BDX

📍 CWCO pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCWCOBDX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CWCO + BDX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CWCO pays
BDX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CWCO
Annual income on $10K today (after 15% tax)
$136.47/yr
After 10yr DRIP, annual income (after tax)
$15,598.35/yr
BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
At 15% tax rate, CWCO beats the other by $14,698.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CWCO + BDX for your $10,000?

CWCO: 50%BDX: 50%
100% BDX50/50100% CWCO
Portfolio after 10yr
$46.7K
Annual income
$9,704.57/yr
Blended yield
20.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDX right now

CWCO
Analyst Ratings
4
Buy
2
Hold
Consensus: Buy
Altman Z
12.3
Piotroski
6/9
BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CWCO buys
0
BDX buys
12
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$BDX▲ Buy$1,001 - $15,0002025-06-17
Rob Bresnahan🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-15
Thomas H. Kean🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-13
Rob Bresnahan🏢 House$BDX▼ Sell$1,001 - $15,0002025-04-08
Jefferson Shreve🏢 House$BDX▼ Sell$15,001 - $50,0002025-03-05
William R. Keating🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-11
Ro Khanna🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-09
John James🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCWCOBDX
Forward yield1.61%2.27%
Annual dividend / share$0.53$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.9%13.5%
Portfolio after 10y$66.4K$26.9K
Annual income after 10y$18,351.00$1,058.14
Total dividends collected$42.2K$5.7K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CWCO vs BDX ($10,000, DRIP)

YearCWCO PortfolioCWCO Income/yrBDX PortfolioBDX Income/yrGap
1$10,936$235.86$10,958$257.59$22.00BDX
2← crossover$12,055$354.11$12,024$299.40+$31.00CWCO
3$13,435$535.94$13,214$348.50+$221.00CWCO
4$15,196$820.00$14,545$406.26+$651.00CWCO
5$17,533$1,273.29$16,038$474.35+$1.5KCWCO
6$20,777$2,016.94$17,715$554.80+$3.1KCWCO
7$25,513$3,281.43$19,606$650.06+$5.9KCWCO
8$32,831$5,531.93$21,741$763.12+$11.1KCWCO
9$44,902$9,773.18$24,161$897.64+$20.7KCWCO
10$66,396$18,351.00$26,910$1,058.14+$39.5KCWCO

CWCO vs BDX: Complete Analysis 2026

CWCOStock

Consolidated Water Co. Ltd., together with its subsidiaries, designs, constructs, manages, and operates water production and water treatment plants primarily in the Cayman Islands, the Bahamas, and the United States. The company operates through four segments: Retail, Bulk, Services, and Manufacturing. It uses reverse osmosis technology to produce potable water from seawater. The company produces and supplies water to end-users, including residential, commercial, and government customers, as well as government-owned distributors. It also provides design, engineering, construction, procurement, and management services for desalination projects and water treatment plants, as well as management and engineering services relating to municipal water distribution and treatment. In addition, the company manufactures and services a range of water-related products, including reverse osmosis desalination equipment, membrane separation equipment, filtration equipment, piping systems, vessels, and custom fabricated components; and provides design, engineering, consulting, management, inspection, training, and equipment maintenance services for commercial, municipal, and industrial water production, supply, and treatment, as well as desalination and wastewater treatment. Consolidated Water Co. Ltd. was incorporated in 1973 and is headquartered in Grand Cayman, the Cayman Islands.

Full CWCO Calculator →

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →
📬

Get this CWCO vs BDX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CWCO vs SCHDCWCO vs JEPICWCO vs OCWCO vs KOCWCO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.